Graham Capital Management L.P. Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Graham Capital Management L.P. acquired a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,506 shares of the biopharmaceutical company's stock, valued at approximately $1,073,000.

Several other institutional investors have also recently made changes to their positions in the stock. Willner & Heller LLC raised its holdings in shares of Regeneron Pharmaceuticals by 3.9% during the fourth quarter. Willner & Heller LLC now owns 399 shares of the biopharmaceutical company's stock valued at $284,000 after purchasing an additional 15 shares during the period. OLD Second National Bank of Aurora raised its holdings in shares of Regeneron Pharmaceuticals by 0.5% during the fourth quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company's stock valued at $2,025,000 after purchasing an additional 15 shares during the period. Rakuten Securities Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 15 shares during the period. TD Private Client Wealth LLC raised its holdings in shares of Regeneron Pharmaceuticals by 9.6% in the 4th quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company's stock worth $122,000 after acquiring an additional 15 shares during the last quarter. Finally, Manchester Capital Management LLC raised its holdings in shares of Regeneron Pharmaceuticals by 12.6% in the 4th quarter. Manchester Capital Management LLC now owns 161 shares of the biopharmaceutical company's stock worth $115,000 after acquiring an additional 18 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN traded up $9.33 on Friday, hitting $594.32. The stock had a trading volume of 935,531 shares, compared to its average volume of 788,324. Regeneron Pharmaceuticals, Inc. has a 52-week low of $520.50 and a 52-week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The company has a market capitalization of $64.17 billion, a price-to-earnings ratio of 15.53, a price-to-earnings-growth ratio of 2.34 and a beta of 0.43. The firm has a 50-day moving average of $599.96 and a 200-day moving average of $684.64.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.03 billion during the quarter, compared to analysts' expectations of $3.40 billion. During the same quarter in the prior year, the company earned $9.55 earnings per share. The business's revenue for the quarter was down 3.7% compared to the same quarter last year. Equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.59%. The ex-dividend date of this dividend is Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.96%.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. The Goldman Sachs Group lowered their target price on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating on the stock in a report on Wednesday, April 30th. UBS Group lowered their target price on shares of Regeneron Pharmaceuticals from $768.00 to $633.00 and set a "neutral" rating on the stock in a report on Wednesday, April 30th. StockNews.com lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 1st. BMO Capital Markets lowered their target price on shares of Regeneron Pharmaceuticals from $865.00 to $800.00 and set an "outperform" rating on the stock in a report on Wednesday, April 30th. Finally, Royal Bank of Canada lowered their target price on shares of Regeneron Pharmaceuticals from $1,051.00 to $943.00 and set an "outperform" rating on the stock in a report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, nineteen have issued a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $890.60.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.